Baricitinib

Long COVID-19

Vanderbilt University Medical CenterSmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

31 Active assets in the Long COVID-19 cohort.

Asset / Sponsor	Phase	Rating
Immulina Tm University of Mississippi Medical Center	Phase 3	BB
Sirolimus Icahn School of Medicine at Mount Sinai	Phase 3	B
Solriamfetol Duke University	Phase 2	B
Melatonin Duke University	Phase 2	B
Paxlovid Kanecia Obie Zimmerman	Phase 2	B

View all 31 →

Same molecule, other indications

Baricitinib is also rated in:

skin disorderDormant

B

Indicative · Phase 2

57 / 100

ischemic strokeActive

B

Indicative · Phase 2/3

57 / 100

psoriasisDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.